Blood Clot Testing Device for Surgery Now Class II Approved
Published Date: 5/9/2025
Rule
Summary
The FDA is officially classifying a blood clot-checking device used during surgery as a Class II device with special safety rules. This change helps make sure the device is safe and works well, while also making it easier for new, helpful devices to reach patients. Hospitals and device makers should get ready for these new rules, which aim to speed up access without extra costs.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Device Classified as Class II
The FDA is officially classifying the coagulation system for measuring whole blood viscoelastic properties in perioperative patients as a Class II medical device with special controls. The agency says this classification provides a reasonable assurance of the device's safety and effectiveness.
Faster Patient Access Through Reduced Burdens
The FDA says this action will enhance patients' access to beneficial innovative devices in part by reducing regulatory burdens, which should make it easier for new devices to reach patients. The summary also notes the change aims to speed up access without extra costs.
Hospitals and Makers Should Prepare
The rule codifies special controls for this device type, and hospitals and device makers are advised to get ready for the new rules. The document indicates these changes are intended to reduce regulatory burdens while ensuring safety and effectiveness.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-08150, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microbial Nucleic Acids by Fluorescence In Situ Hybridization in Clinical Specimens
The FDA is officially putting a special kind of medical device that spots tiny germs in patient samples into a safer, middle-level category called Class II. This change means the device will follow clear safety rules, helping patients get better access to cool new tech without extra red tape. If you make or use these devices, get ready for updated rules that keep things safe and effective, starting now!
Next: 2025-08169, Safety Zone; Fireworks Displays Within the Fifth Coast Guard District; The Wharf, Washington, DC
The Coast Guard is setting up a safety zone around The Wharf in Washington, DC, during a fireworks show to keep everyone safe on the water. Boats won’t be allowed in the area unless they get special permission, and they must follow Coast Guard instructions. This temporary rule helps make sure the fireworks event goes off without a hitch, with no extra costs for boaters who follow the rules.